In the Phase I trial, the duration of response to Regeneron's combination therapy continued beyond two years in melanoma ...

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved blockbuster drug Dupixent (dupilumab) for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) for a broader ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Sell rating on Regeneron (REGN – Research ...

Regeneron, a biotechnology company, teamed up with Binghamton University’s Neurodiversity Club this week to host a panel ...

Regeneron Pharmaceuticals Inc. closed $66.17 short of its 52-week high ($1,211.20), which the company reached on August 27th.

This was the stock's fourth consecutive day of losses.

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...

Stocks to Look After. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) ...

Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with an inflammatory skin disease in a ...

Regeneron is back with long-term follow-up for its LAG-3 inhibitor and PD-1 inhibitor combo in advanced melanoma, phase 1 ...

Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria (CSU), Sanofi and ...